Sacubitril/Valsartan Reduces All-Cause Hospitalizations in Heart Failure Patients with Low LVEF: JAMA
A new study from the PARADIGM-HF and PARAGON-HF clinical trials found that sacubitril/valsartan significantly reduced the risk of hospitalization for any cause, particularly in patients with below-normal left ventricular ejection fraction (LVEF). The …